PMID- 34910320
OWN - NLM
STAT- MEDLINE
DCOM- 20220427
LR  - 20220427
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 47
IP  - 5
DP  - 2022 May
TI  - The efficacy and safety of pimecrolimus 1% cream vs. sertaconazole 2% cream in 
      the treatment of patients with facial seborrhoeic dermatitis: a randomized 
      blinded trial.
PG  - 926-931
LID - 10.1111/ced.15067 [doi]
AB  - BACKGROUND: Facial seborrhoeic dermatitis (FSD) is a chronic inflammatory skin 
      disorder characterized by remission and exacerbation episodes. In most cases, FSD 
      requires long-term treatment. AIM: To compare the efficacy and safety of 
      pimecrolimus and sertaconazole in patients with FSD. METHODS: In total, 60 
      patients with FSD were enrolled in this double-blind, active-controlled, 
      randomized trial, and instructed to topically apply either pimecrolimus 1% cream 
      (30 patients) or sertaconazole 2% cream (30 patients) twice daily for 4 weeks. 
      Assessment of disease severity was performed using the Scoring Index (SI) at 
      baseline, on Days 14 and 28, and at 4 weeks after treatment cessation. The levels 
      of satisfaction from treatment and any adverse effects (AEs) were also assessed 
      in both groups. RESULTS: Although the severity of disease reduced upon treatment 
      in both groups, application of pimecrolimus caused a significantly better 
      improvement than sertaconazole on Days 14 and 28 (P < 0.01 and P < 0.001, 
      respectively). The rate of relapse was significantly lower in the pimecrolimus 
      compared with the sertaconazole group at 4 weeks after treatment cessation 
      (P = 0.01). The highest level of satisfaction (46.7%) was observed on Day 28 in 
      the pimecrolimus group. Both topical treatments had acceptable safety profiles; 
      however, pimecrolimus 1% cream was significantly (P < 0.01) less irritating than 
      sertaconazole 2% cream. CONCLUSION: Pimecrolimus is associated with faster 
      response and fewer AEs than sertaconazole in patients with FSD.
CI  - (c) 2022 British Association of Dermatologists.
FAU - Azizzadeh, Maryam
AU  - Azizzadeh M
AD  - Clinical Research Development Unit (CRDU), Kowsar Hospital, Semnan University of 
      Medical Sciences, Semnan, Iran.
FAU - Pahlevan, Daryoush
AU  - Pahlevan D
AD  - Social Determinants of Health Research Center, Semnan University of Medical 
      Sciences, Semnan, Iran.
FAU - Bagheri, Bahador
AU  - Bagheri B
AD  - Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
AD  - Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
LA  - eng
GR  - 565/CU/CSP VA/United States
GR  - 565/CU/CSP VA/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220125
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Dermatologic Agents)
RN  - 0 (Emollients)
RN  - 0 (Imidazoles)
RN  - 0 (Thiophenes)
RN  - 72W71I16EG (sertaconazole)
RN  - 7KYV510875 (pimecrolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - *Dermatitis, Seborrheic/drug therapy
MH  - *Dermatologic Agents/therapeutic use
MH  - Double-Blind Method
MH  - Emollients/therapeutic use
MH  - Humans
MH  - Imidazoles
MH  - Tacrolimus/adverse effects/analogs & derivatives
MH  - Thiophenes
MH  - Treatment Outcome
EDAT- 2021/12/16 06:00
MHDA- 2022/04/28 06:00
CRDT- 2021/12/15 12:55
PHST- 2021/12/12 00:00 [revised]
PHST- 2021/09/16 00:00 [received]
PHST- 2021/12/14 00:00 [accepted]
PHST- 2021/12/16 06:00 [pubmed]
PHST- 2022/04/28 06:00 [medline]
PHST- 2021/12/15 12:55 [entrez]
AID - 10.1111/ced.15067 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2022 May;47(5):926-931. doi: 10.1111/ced.15067. Epub 2022 Jan 
      25.